SCIEGEN PHARMS
GenericsSCIEGEN PHARMS is a generic drug manufacturer focused on Cardiovascular, Immunology, Gastroenterology.
SCIEGEN PHARMS's Key Drugs
SCIEGEN PHARMS's core commercial portfolio centers on NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, AMLODIPINE AND OLMESARTAN MEDOXOMIL, spanning Cardiovascular and Immunology — its most strategically important drugs approved in the last 15 years.
SCIEGEN PHARMS's Recent FDA Approvals
New NDA/BLA approvals for SCIEGEN PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
SCIEGEN PHARMS's Therapeutic Areas
SCIEGEN PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SCIEGEN PHARMS's Top Competitors
SCIEGEN PHARMS's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SCIEGEN PHARMS Pipeline Snapshot
Active clinical trials for SCIEGEN PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NAPROXEN AND ESOMEPRAZOLE MAGNESIUM leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (4)
Company Info
- First Approval
- 1975-01-08
- Latest
- 2026-06-17
- Applications
- 113